Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HLN US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Haleon plc American Depositary Receipt(HLN US)

$9.07+0.020.22%Ext:$8.84-0.232.54%(Market Closed · 01:00:05 UTC)
Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
All Documents

Financials & Metrics

FinancialsChartingEmployees

Haleon plc American Depositary Receipt — Company Profile

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

Sector
Consumer Discretionary
Industry
Specialty Retail
Exchange
UN
CEO
Brian James McNamara
Headquarters
Weybridge, X0, GB
IPO Date
Jul 25, 2022
Employees
24,535
Website
www.haleon.com

Key Metrics

Price
$8.80
Market Cap
$38.75B
Revenue (TTM)
$11.03B
Net Income (TTM)
$1.63B
EPS (TTM)
0.36
P/E (TTM)
16.08
P/B (TTM)
2.36
Dividend Yield
1.96%
ROE (TTM)
9.94%
ROA (TTM)
5.01%
Operating Margin
21.87%
Beta
-0.02

Dividends

Last Dividend
$0.13
Last Yield
1.96%

Summary

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

Website
www.haleon.com
Location
Weybridge, X0, GB
Phone44 1932 822000
Employees24,535
CEOBrian James McNamara
Sector
Consumer Discretionary
Industry
Specialty Retail
IPO DateJul 25, 2022

Latest Documents

SEC Filings(522)

Expand
  • 6-KTRANSACTIONS IN OWN SHARES16 Nov
  • 6-KTRANSACTIONS IN OWN SHARES9 Nov
  • 6-KDIRECTOR/PDMR SHAREHOLDING2 Nov
  • 6-KTOTAL VOTING RIGHTS AND CAPITAL2 Nov
  • 6-KTRANSACTIONS IN OWN SHARES2 Nov
  • 6-KCOMMENCEMENT OF GBP 500M SHARE BUYBACK PROGRAMME29 Oct
  • 6-KHALEON 2026 Q3 TRADING STATEMENT29 Oct
  • 6-KTOTAL VOTING RIGHTS AND CAPITAL1 Oct
  • 6-KDIRECTOR/PDMR SHAREHOLDING24 Sep
  • 6-KDIRECTOR/PDMR SHAREHOLDING18 Sep
  • 6-KTOTAL VOTING RIGHTS AND CAPITAL1 Sep
  • CERTCERT26 Aug
  • 8-A12BRegistration of securities (Section 12(b))21 Aug
  • 6-KCurrent report (foreign private issuer)21 Aug
  • 6-KCASH TENDER OFFER - PRICING, EXPIRATION AND RESULT19 Aug
  • 6-KTRANSACTIONS IN OWN SHARES & BUYBACK UPDATE19 Aug
  • 6-KTRANSACTIONS IN OWN SHARES17 Aug
  • 424B5Prospectus filing (Rule 424(b)(5))13 Aug
  • 6-KLAUNCH & PRICE: $2BN THREE-TRANCHE BOND OFFERING13 Aug
  • FWPFree writing prospectus12 Aug

News

  • ASAIY vs. HLN: Which Stock Is the Better Value Option?17 Nov
  • Buy 18 Ideal 'Safer' November Dividend Dogs Of 10-Year Tenured 8111 Nov
  • BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) Head to Head Contrast6 Nov
  • Haleon plc (HLN) Q3 2026 Sales/Trading Call Transcript29 Oct
  • ASAIY or HLN: Which Is the Better Value Stock Right Now?29 Oct
  • UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon20 Oct
  • Haleon Launches ‘Haleon Health House,' a One-Day Interactive Wellness Pop-Up in Toronto19 Oct
  • Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore12 Oct
  • Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors5 Oct
  • Unilever on JP Morgan positive watch as Haleon faces caution5 Oct
  • LCUT vs. HLN: Which Stock Is the Better Value Option?28 Sep
  • Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs16 Sep
  • LCUT or HLN: Which Is the Better Value Stock Right Now?11 Sep
  • Haleon secures better shelf space at Walmart, Target in bid to boost market share3 Sep
  • Comparing Haleon (NYSE:HLN) & Procter & Gamble (NYSE:PG)31 Aug
  • LCUT vs. HLN: Which Stock Is the Better Value Option?26 Aug
  • Jefferies raises Haleon price target to 410p on margin strength24 Aug

Mentions in Filings

  • F
    … . Mr. Young also serves as a director of Johnson Controls International, and previously served as a director and chair of the compensation committee of Arvinas Inc. from August 2022 until June 2025, and as a director of <strong>Haleon plc</strong> from July 2022 until March 2023. Mr. Young received a Bachelor’s degree in Biological Sciences from the University of Glasgow and a Master of Business Administration from the University of Strathclyde. Slate’s board of …
    Fulcrum Therapeutics, Inc.Haleon plc American Depositary Receipt·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·4 Nov
  • F
    … . Mr. Young also serves as a director of Johnson Controls International, and previously served as a director and chair of the compensation committee of Arvinas Inc. from August 2022 until June 2025, and as a director of <strong>Haleon plc</strong> from July 2022 until March 2023. Mr. Young received a Bachelor’s degree in Biological Sciences from the University of Glasgow and a Master of Business Administration from the University of Strathclyde. Slate’s board of …
    Fulcrum Therapeutics, Inc.Haleon plc American Depositary Receipt·S-4/A - Registration statement (business combination, amendment)·Q4 26·3 Nov
  • D
    … phies of this segment: “Emerging Markets” (which is comprised of Russia, other countries of the former Soviet Union, Romania and certain other countries from our “Rest of the World” markets, including Brazil, South Africa, Colombia, Vietnam and China), India and Europe (which also includes the global portfolio outside of the United States of consumer brands in the Nicotine Replacement Therapy category acquired from <strong>Haleon</strong> UK (the “NRT business”).
    DR REDDYS LABORATORIES LTDHaleon plc American Depositary Receipt·6-K - Current report (foreign private issuer)·Q3 27·23 Oct
  • F
    … . Mr. Young also serves as a director of Johnson Controls International, and previously served as a director and chair of the compensation committee of Arvinas Inc. from August 2022 until June 2025, and as a director of <strong>Haleon plc</strong> from July 2022 until March 2023. Mr. Young received a Bachelor’s degree in Biological Sciences from the University of Glasgow and a Master of Business Administration from the University of Strathclyde. Slate’s board of …
    Fulcrum Therapeutics, Inc.Haleon plc American Depositary Receipt·S-4/A - Registration statement (business combination, amendment)·Q4 26·20 Oct
  • U
    … | | | | | (1,186,954,872) | | | | | British pound | GLENCORE PLC | 99,380 | 5.19 | 516,080.34 | | | British American Tobacco PLC | 9,549 | 45.57 | 435,147.93 | | | | ASTRAZENECA PLC | 5,260 | 153.26 | 806,147.60 | | | | <strong>HALEON PLC</strong> | 99,164 | 4.05 | 402,308.34 | | | | WISE PLC - A | 26,134 | 8.33 | 217,696.22 | | | | subtotal | | 239,487 | | 2,377,380.43 | | | | | (500,200,842) | | | | | Swiss franc | ALCON INC | 9,023 | 64.26 | 579,817.98 | | | S …
    UBSアセット・マネジメント株式会社Haleon plc American Depositary Receipt·Prospectus - Securities registration statement·20 Nov·19 Nov
  • 三
    … | US Dollars Subtotal | | 8,898,022 | | 1,822,856,074.24 | | | | | (289,487,773,150) | | | | | British pound | EXPERIAN PLC | 1,823,670 | 29.49 | 53,780,028.30 | | | RELX PLC | 1,683,649 | 26.12 | 43,976,911.88 | | | | <strong>HALEON PLC</strong> | 12,961,702 | 3.63 | 47,063,939.96 | | | | British Pounds Subtotal | | 16,469,021 | | 144,820,880.14 | | | | | (31,398,615,023) | | | | | New Taiwan Dollar | TAIWAN SEMICONDUCTOR MANUFAC | 1,965,000 | 2,410.00 | 4,735, …
    三菱UFJアセットマネジメント株式会社Haleon plc American Depositary Receipt·Prospectus - Amended Securities Registration Statement·20 Nov·19 Nov

Key Stats

Trading

Px/Chg 1D$8.80 / +0.92%
Avg Volume9.09M
Beta-0.02
Mkt Cap38.75B
FD Mkt Cap44.52B

Float

Shrs Out/Float4.40B / 4.43B
Short Float0.00%
Days to Cover1.25
Stock Repurchased$639.67M

Current Valuation

EV46.08B
EV/EBITDA11.41
EV/Sales2.79
P/B2.36
P/S2.34
FCF Yield3.24%
ROE9.94%
ROA5.01%
Current Ratio0.92

Dividend

Cash$0.13
Yield1.96%
Yield (TTM)1.96%

Estimates

P/E16.08
Est P/E0.00
Est EPS0.25
Est PEG0.00

Valuation

Metric5Yr AvgJun '23Mar '24Mar '25Oct '26
PRICE-BASED RATIOS
Price / Earnings37.7535.8137.4832.4245.29
Price / Sales4.543.503.484.167.03
Price / Book Value2.492.322.372.892.36
Price / Free Cash Flow24.4521.8822.2922.8030.84
ENTERPRISE VALUE METRICS
Enterprise Value49,124.947,837.947,856.454,720.846,084.5
Enterprise Value / Sales5.474.414.234.878.36
Enterprise Value / EBITDA24.0521.9120.3621.7732.16
Enterprise Value / EBIT27.2825.2323.4423.6136.86

Financials

Full Financials
Millions GBP5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue3.7%9,545.010,858.011,302.011,233.011,030.0
Gross Income4.1%5,950.06,577.06,961.06,948.06,987.4
EBITDA6.8%2,211.02,183.02,351.02,514.02,879.5
EBIT6.8%1,943.01,896.02,042.02,318.02,527.4
Net Income4.1%1,390.01,060.01,049.01,442.01,630.5
EPS (Diluted)4.7%0.300.240.240.320.36
BALANCE SHEET
Cash & ST Inv33.7%414.0684.01,044.02,250.01,321.7
Total Assets-1.4%34,451.034,815.034,055.034,315.032,572.6
Total Liabilities19.2%7,971.018,358.017,326.018,091.016,117.6
Total Shareholder Equity-11.2%26,355.016,331.016,606.016,166.016,396.1
CASH FLOW
Net Operating Cash Flow13.9%1,356.02,063.02,100.02,301.02,285.8
Cap Ex1.4%-298.0-328.0-336.0-250.0-314.9
Free Cash Flow16.8%1,058.01,735.01,764.02,051.01,970.8

Enterprise Value Bridge

Millions GBP20 Nov '26
Price (As of 20 Nov '26)9.08
Basic Shares4,403.80
Market Cap39,986.5
Diluted Shares4,460.00
Fully Diluted Shares Outstanding4,460.00
Fully Diluted Market Cap40,496.8
+Consolidated Debt8,202.2
−In-the-Money Convertible Debt—
+Capital Leases110.3
+Operating Leases—
−Cash & Equivalents-821.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest59.6
+Pension Liabilities—
Enterprise Value47,427.3

Segment data

Revenue

by Products and services

  • Respiratory Health65%
  • Digestive Health35%

Revenue

by Geography

  • Rest Of World56%
  • United States35%
  • China9%

Related companies

Colgate Palmolive Co

CL US

Bandai Namco Holdings Inc.

NCBDY US

Estee Lauder Companies Inc

EL US

Kenvue Inc.

KVUE US

ANTA Sports Products Ltd / ADR

ANPDY US

Pop Mart International Group Limited/ADR

9992 HK

Clorox Co /DE/

CLX US

Life Time Group Holdings, Inc.

LTH US

Games Workshop Group Plc/adr

GMWKF US

Chemed Corp

CHE US

e.l.f. Beauty, Inc.

ELF US

Acushnet Holdings Corp.

GOLF US